Cantor Fitzgerald Starts Avalo Therapeutics Inc. (AVTX) at Overweight

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Overweight rating.

The analyst comments "We are initiating coverage of Avalo Therapeutics (AVTX) with an Overweight rating. Avalo is a clinical-stage biotech focused on autoimmune diseases. Its lead drug, AVTX-009, is an IL-1β antibody currently in a Phase 2 trial for Hidradenitis Suppurativa (HS) – a severe skin disease. Ph2 HS trial is guided to read out in mid-2026."

For an analyst ratings summary and ratings history on Avalo Therapeutics Inc. click here. For more ratings news on Avalo Therapeutics Inc. click here.

Shares of Avalo Therapeutics Inc. closed at $8.95 yesterday.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Jefferies Starts Aehr Test Systems (AEHR) at Buy
• Kotak Upgrades Max Financial Services (MAXF:IN) to Buy (1)